SCHEMBL6673361

SCHEMBL6673361

COC(=O)c1c(F)cc(C(=O)Nc2cc(C(C)(C)C)nc(C(C)(C)C)c2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.44
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTPN11 Q06124 1/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
ATM Q13315 1/20 0.40
ENPP2 Q13822 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC6 Q9UBN7 2/20 0.37
HDAC3 O15379 1/20 0.37
KCNQ3 O43525 3/20 0.37
KCNQ2 O43526 3/20 0.37
KCNQ5 Q9NR82 2/20 0.37
KCNE1 P15382 1/20 0.37
KCNQ1 P51787 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6672974 0.86 RARA (0.47) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL6693165 0.84 HDAC3 (0.48) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL6673833 0.75 RARA (0.53) LMNAALDH1A1MEN1KMT2ARAB9A
SCHEMBL24132657 0.75 MAPT (0.49) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL6675739 0.75 SMN1; SMN2 (0.44) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL9543676 0.72 MAPT (0.38) MAPTKDM4ELMNAALDH1A1KMT2A
SCHEMBL6674449 0.72 MEN1 (0.55) LMNAMEN1KMT2AL3MBTL1RAB9A
SCHEMBL6673464 0.71 RAB9A (0.59) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL522695 0.71 KDM4E (0.57) MAPTKDM4ELMNAALDH1A1MEN1
SCHEMBL6676184 0.70 POLB (0.49) MAPTKDM4ELMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0862555-B1 SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN INC (US) 2004-10-20 EP claimed
US-20020091262-A1 Substituted aryl or heteroarylamides having retinoid-like biological activity ALLERGAN 2002-07-11 US claimed
EP-0862555-A1 SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY Allergan (US) 1998-09-09 EP claimed
US-5663357-A COMPOUNDS FOR TREATMENT OF SKIN DISORDERS ALLERGAN (US) 1997-09-02 US claimed
WO-1997019062-A1 SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN (US) 1997-05-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091262-A1 Substituted aryl or heteroarylamides having retinoid-like biological activity CCR8, RXRA, CBR1 MAPT 4839/4885KDM4E 2986/4885LMNA 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.